The UK biotech sector, known for its innovation and early-discovery pipelines, has long relied on the U.S. as a first launch market, with many biotechs aiming to leverage the higher drug pricing in the U.S. to drive value. However, the evolving U.S. policy landscape; including the announcement of the Most Favoured Nation (MFN) executive order, the imposition of tariffs, and ongoing delays within the regulatory processes, has introduced substantial uncertainty.
To explore the strategic implications of these policy shifts, Blue Matter convened a roundtable discussion with UK biotech leaders on 14th May 2025. The meeting was attended by 16 senior leaders from different firms from across London, Oxford and Cambridge, each focused on unique indications and treatment modalities. These executives were divided into a series of small groups, each of which examined a key topic within the policy landscape before sharing their insights and conclusions to the entire assembly.
This paper summarizes the group’s insights and recommendations for UK-based biotech firms.
The UK Biotech Club:
The UK Biotech Club is an ongoing series of events organized by Blue Matter and focused on topics of interest to senior leaders in UK-based biotech firms. Each event typically involves 20-25 C-suite executives who gather to network and discuss important strategic issues in a private setting. If you are a senior executive in a UK-based biotech firm and are interested in attending these events, then please contact Pankaj Oza at poza@bluematterconsulting.com.
